Many tumours that grow progressively do so despite the ability of the host to offer defences in the form either of natural immunity, e.g. natural killer cells, or of specifically acquired immunity, e.g. cytotoxic T-cells or activated macrophages delivered by delayed-type hypersensitivity reactions (Herberman & Ortaldo, 1981; Doherty et al., 1984; Robins & Baldwin, 1985) .
One of the ways in which tumours can resist the operation of natural or acquired immune defences is by producing factors that interfere with the operation of those defences. We have examined many tumours, of different types and species of origin, and have found that all produce factors that depress the expression of cell-mediated immunity, in the form of delayed-type hypersensitivity (DTH) reactions in mice (Nelson et al., 1981; Nelson & Nelson, 1987) . In vitro, tumour culture supernatants inhibited the production of interleukin 1 (ILl) by mouse macrophages and macrophage chemotactic factor and interleukin 2 (IL2) by mouse spleen cells (Farram et al., 1982; . Hersey et al. (1983) have also reported that some melanoma culture supernatants inhibited the production of IL2 by human blood lymphocytes.
Because IL2 is central to the expression of cell-mediated immunity we have studied further the effects of tumour cell culture supernatants on its production. Cells of the mouse thymoma EL4, stimulated either by concanavalin A (ConA), as concanavalin A-Sepharose (Pharmacia, Uppsala) or by phorbol myristate acetate (PMA) and the calcium ionophore A23187, produced 20-80% less IL2 in the presence of any of a variety of tumour culture supernatants . As production in this system is independent of ILl, it is thus clear that IL2 production can be inhibited independently of any effect of tumour products on ILl production. A similar conclusion was drawn by Hersey et al. (1983) , who could not, in fact, detect any inhibition of ILl production by human blood monocytes in the presence of melanoma supernatants. With EL4 cells, inhibition of IL2 production was selective, in that it was inhibited to a greater degree than was general protein synthesis in EL4 cells, and general protein synthesis in fibroblasts was not inhibited.
A further important question, however, is whether IL2 production is truly inhibited, or whether tumour cell products stimulate the synthesis of an inhibitor of IL2 activity, such as 'contra-IL2' (Maki et al., 1986) . This can be answered with reasonable certainty by comparing IL2 measured in a functional assay with IL2 measured in an immunoassay. This is most readily done with human lymphocytes, as immunoassays for human IL2 are available commercially.
Mononuclear leukocytes were separated from the peripheral blood of normal human donors by standard methods, using Ficoll-Hypaque discontinuous gradient centrifugation. They were cultured in serum-free RPMI 1640 medium (Gibco, Grand Island, NY, USA) containing 28mM Hepes buffer, penicillin (100 U ml-1), streptomycin (100 ugml-1), After culture for 24h the supernatants were collected and assayed for IL2, either immediately or after storage at -70°C.
The mouse IL2-dependent T-cell line CTLL was used for functional assays of IL2, essentially as described by Gillis et al. (1978) . The CTLL cells were maintained in Dulbecco's modified Eagle's medium (DME, Gibco), with 10% heated (56°C, 30min) fetal calf serum (FCS, Flow Laboratories, Sydney), 5 x 10-5 M 2-mercaptoethanol, glucose (4 mg ml-1) and IL2 (20-30 U ml-). The IL2 was either purified human rIL2 (Boehringer Mannheim, FR Germany) or a crude preparation containing mouse IL2, from EL4 cells stimulated with PMA (10ngml-1) and the ionophore A23187 (50 ng ml-1; Sigma). For assays of IL2, serial doubling dilutions of the human lymphocyte culture supernatants were made in RPMI 1640 (with transferrin and insulin). Thricewashed CTLL cells were suspended (1-2x 10 ml-1) in RPMI 1640 medium containing 10-4 M 2-mercaptoethanol, glucose (8mgml-1) and 20% heated FCS. Triplicate 50pl1 samples of lymphocyte culture supernatants were mixed with 50l of CTLL suspension in the wells of flat-bottomed 96-well plates (Linbro, Maclean, VA) and incubated for 24h. Tritiated thymidine incorporation was measured over the last 4h. One unit of IL2 is defined as the amount required to give half the maximal incorporation of tritiated thymidine. Thus, the apparent inhibition of IL2 production is due neither to the production of a functional inhibitor of IL2 nor to an inhibitor of DNA synthesis (Werkmeister et al., 1980) . It remains to be seen whether the inhibitory effect of tumour products is exerted at a pre-or post-transcriptional level. It is possible that inhibition of IL2 production is secondary, wholly or in part, to inhibition of ILl production. Other studies with mouse lymphoid cells indicate that inhibition of IL2 production can occur independently of inhibition of ILl production (Wanebo et al., 1986; Elliott et al., 1987) . Perhaps more importantly, they may be responsible for the lack of antitumour effectiveness of tumour-associated lymphocytes which, when isolated and cultured with IL2, can give rise to potent lymphokine-activated killer (LAK) cells (Belldegrun et al., 1988) . The induction of resistance to such products (e.g. by immunisation) might offer a novel approach to immunological intervention in cancer, and could perhaps obviate the need for large and toxic doses of IL2 in immunotherapy involving LAK cells (Rosenberg et al., 1987) .
